Will Myovant Sciences Ltd. (MYOV) Short Squeeze Soon? The Stock Formed a Double Top Pattern

September 16, 2018 - By Kristen Paramore

The chart of Myovant Sciences Ltd. (MYOV) shows a double top with $25.47 target or 7.00 % above today’s $23.80 share price. The 7 months chart pattern indicates low risk for the $1.62 billion company. It was reported on Sep, 16 by Finviz.com. If the $25.47 price target is reached, the company will be worth $113.68M more. Double tops are rare but powerful chart patterns.

The stock decreased 1.12% or $0.27 during the last trading session, reaching $23.8. About 27,171 shares traded. Myovant Sciences Ltd. (NYSE:MYOV) has risen 81.96% since September 16, 2017 and is uptrending. It has outperformed by 66.34% the S&P500.

Analysts await Myovant Sciences Ltd. (NYSE:MYOV) to report earnings on November, 12. They expect $-0.96 EPS, down 92.00 % or $0.46 from last year’s $-0.5 per share. After $-0.98 actual EPS reported by Myovant Sciences Ltd. for the previous quarter, Wall Street now forecasts -2.04 % EPS growth.

More recent Myovant Sciences Ltd. (NYSE:MYOV) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on September 13, 2018. Also Benzinga.com published the news titled: “Benzinga’s Top Upgrades, Downgrades For September 13, 2018” on September 13, 2018. Streetinsider.com‘s news article titled: “JPMorgan Starts Myovant Sciences Ltd. (MYOV) at Overweight” with publication date: September 13, 2018 was also an interesting one.

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company has market cap of $1.62 billion. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It currently has negative earnings. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.